China's YiChang HEC hits three-month high on drug launch approval

Yichang Hec Changjiang Pharmaceutical Co

29/06/2021 04:45

** Shares of YiChang HEC ChangJiang Pharmaceutical Co Ltd
 1558.HK  rise 11.3% to HK$9.18, their highest since March 24
    ** Stock last up 11.03%, among the 30 biggest percentage
gainers on the Hong Kong bourse
    ** Stock on course for a third straight session of gains
    ** Hubei-based co says China National Medical Products
Administration has approved launch of its atorvastatin calcium
tablets for use in hypercholesterolemia  urn:newsml:reuters.com:*:nFWN2OA0K2
    ** The Hong Kong Hang Seng Commerce & Industry Index  .HSNC 
slips 0.8%, and the healthcare index  .HSCIH  falls 1.4%
    ** The Hang Seng China Enterprises Index  .HSCE  eases 0.9%,
and the benchmark index  .HSI  declines 0.7%
    ** As of last close, stock had slid 6.6% this year

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))